Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As VC Investments Rebound In Q2, Skepticism Lingers

This article was originally published in The Pink Sheet Daily

Executive Summary

A quarterly report shows an uptick in VC disbursements, but LP commitments are still lagging.

You may also be interested in...



Financings Of The Fortnight Sees More Conflicting Indicators For Biotech VC

Quarterly trends suggest the outlook may turn sunny, plus financings updates on NuPathe, Euthymics Bioscience, Xoma and Immune Design Corp.

Financings Of The Fortnight Sees More Conflicting Indicators For Biotech VC

Quarterly trends suggest the outlook may turn sunny, plus financings updates on NuPathe, Euthymics Bioscience, Xoma and Immune Design Corp.

Euthymics' Sweet Dreams Could Be Realized With $24MM Series A

The startup will resume trials on a novel antidepressant lost in the shuffle when DOV Pharmaceuticals ceased operations.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070907

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel